1. Centers for Disease Control. Coronavirus Disease 2019 (COVID-19) in the U.S. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html. Accessed September 27, 2020.
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507-13.
3. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Welein C, Stark H, Tazankov A, Wi WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;DOI:1010156/NEJMoa2015432 [Epub ahead of print].
4. Brune K, Frank J, Schwingshackl A, Finigan J, Venkataramana, SK. Pulmonary epithelial barrier function: some new players and mechanisms. Am J Physiol Lung Cell Mol Physiol 2015;308(8): L731-L745.
5. Siddiqi HK and Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart and Lung Transplant 2020;39(5):405-7.
6. Zhang C, Wu Z, Li JW, Zhao H, Wang G. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonisttTocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020;55(5):105954.
7. Coomes EA and Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis. MedRxiv 2020;DOI:10.1101/2020.03.30.20048058. (pre-print)
8. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor t cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018;23(8):943-947.
9. Giamarellos-Bourboulis EJ, et al. et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27(6):992-1000.e3.
10. Alzghari SK and Acuna VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol 2020;127:104380.
11. Luo P, Liu Y, Qiu L, Lui X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;92(7):814-8.
12. Xu X, Mingfeng H, Tiantian L, Sun W, Wang D, Fu B, Zhou W, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. Proc Natl Acad Sci USA 2020;117(20):10970-5.
13. Sciascia S, Apra F, Baffa A, Baldovino S, Boara D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Perri GD, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D. Pilot prospective open, single arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumato 2020;38(3):529-32.
14. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, Cossi S. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med 2020; 76:31-5.
15. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dollman NO, Frame D, Gregg KS, Kaul DR, Nagel J, Patel TS, Zhou S, Lauring AS, Hanauer DA, Martin E, Sharma P, Fung CM, Pogue JM. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. medRxiv 2020;DOI:10.1101/2020.05.29.20117358. (preprint)
16. Price CC, Altice FL, Shyr MY, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen S-C, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Cruz CD, Malinis M. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-10 patients: survival and clinical outcomes. Chest 2020;DOI:10.1016/j.chest.2020.06.006.(In press)
17. Guaraldi G, Meschiari M, Gozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini R, Cuomo G, Orlando G, Borghi V, Santoro A, Di Gaetano M, Puzzolante C, Carli F, Bedini A, Corradi L, Fantini R, Castaniere I, Tabbi L, Girardis M, Tedeschi S, Gianella M, Bartoletti M, Pascale R, Dolci G, Brugiono L, Pietrangelo A, Cossarizza A, Pea F, Clini E, Salvarani C, Massari M, Viale PL, Mussini C. Tocilizumab in patients with severe COVID-10: a retrospective cohort study. Lancet Rhematol 2020:2(8):e474-84. DOI:10.1016/S2665-9913(20)30173-9. (Epub ahead of print)
18. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S Sinclaire BA, Bednarz U, Marafelias M, Hansen E, Siegel DS, Goy AH, Pecora AL, Sawczuk I, Koniaris LS, Simwenyi M, Varga DW, Tank LK, Stein AA, Allusson V, Lin GS, Oser WF, Ruma RA, Reichman J, Brusco Jr L, Carpenter KL, Costanzo EJ, Vivona V, Goldberg SL. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rhematol 2020;2(10):e603-2. DOI:10.1016/S2665-9913(20)30173-9. (Epub ahead of print)
19. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zhend Z, Rose-John S, White JC, Nazimuddin F, Wetheim G, Levine BL, June CH, Porter DL, Grupp SA. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov 2016;6(6):664-679.
20. China's National Health Commission. Novel Coronavirus Treatment Guidelines – 7th Edition. 2020.
21. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest 2007;132,410-417.
22. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533.
23. World Health Organization. WHO R&D Blueprint novel Coronavirus: COVID-19 Therapeutic Trial Synopsis. 2020.
24. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA). Available from https://clinicaltrials.gov/ct2/show/NCT04372186. Accessed September 27, 2020.
25. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA). Available from https://clinicaltrials.gov/ct2/show/NCT04409262. Accessed September 27, 2020.
26. Lippi G and Plebani M. Laboratory abnormality in patients with COVID-2019 infection. Clin Chem Lab Med 2020;58(7):1131-4.
27. Actemra (tocilizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; 2020.
28. Nishimoto N, et al. Mechanisms and pathologic significance in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959-64.
29. Rimland CA, Morgan CE, Bell GJ, Kim MK, Hedrick T, Marx A, Bramson B, Swygard H, Napravnik S, Schmitz JL, Carson SS, Fischer WA, Eron JJ, Gay CL, Parr JB. Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center. medRxiv 2020;DOI:10.1101/2020.05.13.20100404. (preprint)
30. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, Tomelleri A, Baldissera E, Rovere-Querini P, Ruggeri A, Monti G, De Cobelli F, Zangrillo A, Tresoldi M, Castagna A, Dagna L. Efficacy and safety of tocilizumab in severe in COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med 2020;76:43-9.
31. Kimmig LM, Wu D, Gold M, Pettit NN, Pitrak D, Mueller J, Husain AN, Mutlu EA, Mutlu GM. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. medRxiv 2020;DOI:10.1101/2020.05.15.20103531. (preprint)
32. Horby P, Lim WS, Emberson J, Mafmam M, Bell J, Linsell L, Staplin N, Brightling C, Ustanowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwich D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ, RECOVERY Collaborative Group. medRxiv 2020;DOI:10.1101/2020.06.22.20137273. (preprint)
33. Navarro G, Taroumian S, Barroso N, Duan L, Furst D. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical outcomes. Semin Arthritis Rheum 2014;43(4):458-69.
34. Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, Riddell SR, Maloney DG, Boeckh M, Turtle CJ. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 2018;131(1):121-30.